Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | GHSR | Q92847 | 4/20 | 0.47 |
| ▸ | NAMPT | P43490 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377453 | 0.89 | POLB (0.42) | FABP4NAMPTLMNAMEN1KMT2A | |
| SCHEMBL19377027 | 0.85 | IDH1 (0.58) | GHSRNAMPTLMNAHTTMEN1 | |
| SCHEMBL19377395 | 0.80 | HSD17B10 (0.58) | GHSRNAMPTLMNAMEN1KMT2A | |
| SCHEMBL19377105 | 0.79 | GPR27 (0.56) | LMNASMN1; SMN2 | |
| SCHEMBL19377106 | 0.79 | GPR27 (0.56) | LMNASMN1; SMN2 | |
| SCHEMBL19377464 | 0.77 | GHSR (0.51) | GHSRLMNAHTTMEN1KMT2A | |
| SCHEMBL19377465 | 0.77 | GHSR (0.51) | GHSRLMNAHTTMEN1KMT2A | |
| SCHEMBL19377335 | 0.77 | GHSR (0.50) | GHSRNAMPTMEN1KMT2AIDH1 | |
| SCHEMBL19377339 | 0.77 | GHSR (0.50) | GHSRNAMPTMEN1KMT2AIDH1 | |
| SCHEMBL19398865 | 0.76 | GHSR (0.55) | GHSRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | claimed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| WO-2017162390-A1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | FABP4 229/4885GHSR 2/4885NAMPT 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.